Patents by Inventor Christian Scheckermann
Christian Scheckermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160304575Abstract: The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or recombinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies.Type: ApplicationFiled: July 1, 2016Publication date: October 20, 2016Inventors: Christian Scheckermann, Dietmar Eichinger, Stefan Arnold
-
Patent number: 9222081Abstract: The present invention relates to a method for the production and purification of a sialyltransferase polypeptide, in particular a N-Acetylgalactosamine (Gal NAc)-?-2,6-sialyltransferase I (ST6GalNAcI) polypeptide. The method comprises the steps of producing the sialyltransferase polypeptide in a Chinese Hamster Ovary (CHO) cell and purifying the polypeptide with a combination of chromatography steps. The method results in high yield of sialyltransferase polypeptide which is highly pure and active. The obtained sialyltransferase, especially ST6GalNAcI, can be employed for the glycosylation of therapeutic proteins such as G-CSF.Type: GrantFiled: August 2, 2011Date of Patent: December 29, 2015Assignee: BIOGENERIX GMBHInventors: Axel Angermann, Christian Scheckermann, Karsten Schmidt
-
Publication number: 20150353599Abstract: The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or recombinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies.Type: ApplicationFiled: June 15, 2015Publication date: December 10, 2015Inventors: Christian Scheckermann, Dietmar Eichinger, Stefan Arnold
-
Patent number: 9096683Abstract: The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or recombinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies.Type: GrantFiled: April 1, 2010Date of Patent: August 4, 2015Assignee: Ratiopharm GMBHInventors: Christian Scheckermann, Dietmar Eichinger, Stefan Arnold
-
Patent number: 8703123Abstract: Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity.Type: GrantFiled: March 17, 2011Date of Patent: April 22, 2014Assignee: BioGeneriX GmbHInventors: Walter Hinderer, Christian Scheckermann
-
Publication number: 20140057316Abstract: The present invention relates to a method for the production and purification of a sialyltransferase polypeptide, in particular a N-Acetylgalactosamine (Gal NAc)-?-2,6-sialyltransferase I (ST6GalNAcI) polypeptide. The method comprises the steps of producing the sialyltransferase polypeptide in a Chinese Hamster Ovary (CHO) cell and purifying the polypeptide with a combination of chromatography steps. The method results in high yield of sialyltransferase polypeptide which is highly pure and active. The obtained sialyltransferase, especially ST6GalNAcI, can be employed for the glycosylation of therapeutic proteins such as G-CSF.Type: ApplicationFiled: February 2, 2011Publication date: February 27, 2014Applicant: BIOGENERIX GMBHInventors: Axel Angermann, Christian Scheckermann, Karsten Schmidt
-
Patent number: 8546328Abstract: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.Type: GrantFiled: August 27, 2008Date of Patent: October 1, 2013Assignee: BioGeneriX AGInventors: Walter Hinderer, Christian Scheckermann
-
Publication number: 20120328560Abstract: Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity.Type: ApplicationFiled: March 17, 2011Publication date: December 27, 2012Applicant: BIOGENERIX AGInventors: Walter Hinderer, Christian Scheckermann
-
Publication number: 20120177603Abstract: A method for the production of human glycosylated Interferon-beta (IFN-?) is described, comprising two affinity chromatography steps followed by hydrophobic interaction chromatography step preferably with a subsequent anion exchange chromatography step. IFN-? obtained by the method as described is characterized by a high purity and specific biologically activity, because of which it is particularly suitable for the production of pharmaceutical compositions.Type: ApplicationFiled: July 7, 2010Publication date: July 12, 2012Applicant: BioGenerix AGInventors: Stefan Arnold, Christian Scheckermann
-
Patent number: 8207112Abstract: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and/or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.Type: GrantFiled: August 29, 2008Date of Patent: June 26, 2012Assignee: BioGeneriX AGInventors: Walter Hinderer, Christian Scheckermann
-
Publication number: 20120135928Abstract: The present invention relates to a method for purifying a recombinant follicle stimulating hormone (FSH) or re-combinant FSH variant. The method comprises the steps of subjecting a liquid containing a recombinant FSH or recombinant FSH variant to an anion exchange chromatography, to a hydrophobic interaction chromatography, and to a dye affinity chromatography, wherein these chromatographies may be performed in any order, and wherein the method neither comprises a weak anion exchange chromatography nor a reverse phase chromatography. The method of purification results in a high yield of recombinant FSH having a desired degree of purity. The obtained FSH is especially useful for the prophylaxis and treatment of disorders and medical indications where FSH preparations are considered as useful remedies.Type: ApplicationFiled: April 1, 2010Publication date: May 31, 2012Applicant: BIOGENERIX AGInventors: Christian Scheckermann, Dietmar Eichinger, Stefan Arnold
-
Publication number: 20110053844Abstract: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.Type: ApplicationFiled: August 27, 2008Publication date: March 3, 2011Inventors: Walter Hinderer, Christian Scheckermann
-
Publication number: 20090143292Abstract: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and/or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.Type: ApplicationFiled: August 29, 2008Publication date: June 4, 2009Applicants: Neose Technologies, Inc., BioGeneriX AGInventors: Walter Hinderer, Christian Scheckermann